Recent News

• 09.15.2025 - vTv Therapeutics Will Participate in INNODIA Symposium at the EASD 61st Annual Meeting
• 09.10.2025 - Morgan Stanley 23rd Annual Global Healthcare Conference
• 09.03.2025 - UPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences
• 09.03.2025 - UPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences
• 09.03.2025 - vTv Therapeutics to Participate in Upcoming September Investor Conferences
• 09.02.2025 - vTv Therapeutics Announces $80 Million Private Placement with Leading Healthcare Institutional Investors and the T1D Fund
• 09.02.2025 - vTv Therapeutics Announces $80 Million Private Placement with Leading Healthcare Institutional Investors and the T1D Fund
• 08.12.2025 - vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
• 08.12.2025 - vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
• 08.11.2025 - vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin

Recent Filings

• 09.10.2025 - 8-K Current report
• 09.08.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 09.08.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 09.05.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.05.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.03.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 09.02.2025 - 8-K Current report
• 08.12.2025 - 8-K Current report
• 08.12.2025 - EX-99.1 EX-99.1
• 08.12.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]